# PRODUCT INFORMATION



## Carvedilol-d<sub>5</sub> Item No. 25218

CAS Registry No.: 929106-58-1

Formal Name: 1-(9H-carbazol-4-yloxy)-3-[[2-(2-

methoxyphenoxy)ethyl]amino]-2-propan-

1,1,2,3,3-d<sub>5</sub>-ol

MF:  $C_{24}H_{21}D_5N_2O_4$ 

411.5 FW:


**Chemical Purity:** ≥98% (Carvedilol)

Deuterium

≥99% deuterated forms  $(d_1-d_5)$ ; ≤1%  $d_0$ Incorporation:

Supplied as: Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



## **Laboratory Procedures**

Carvedilol-d<sub>5</sub> is intended for use as an internal standard for the quantification of carvedilol (Item No. 15418) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Carvedilol- $d_{5}$  is supplied as a solid. A stock solution may be made by dissolving the carvedilol- $d_{5}$  in the solvent of choice, which should be purged with an inert gas. Carvedilol- $d_5$  is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of carvedilol- $d_5$  in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF

#### Description

Carvedilol is a non-selective antagonist of the  $\beta$ -adrenergic receptor ( $\beta$ -AR;  $K_d$ s = 1.78, 0.4, and 5.01 nM for  $\beta_1$ -,  $\beta_2$ -, and  $\beta_3$ -ARs, respectively).<sup>1</sup> It also binds to  $\alpha_1$ -, but not  $\alpha_2$ -, adrenergic receptors (K<sub>i</sub>s = 0.81) and 3,400 nM, respectively).<sup>2</sup> Carvedilol reverses increases in heart rate induced by the  $\beta_1$ -AR agonist isoproterenol (Item No. 15592) in isolated guinea pig atria ( $K_b = 0.8 \text{ nM}$ ) and induces relaxation of isolated precontracted guinea pig trachea ( $K_b = 1.3 \text{ nM}$ ).<sup>3</sup> It prevents epinephrine-induced premature ventricular beats in a rat model of arrhythmia with an  $ED_{50}$  value of 0.25 mg/kg. <sup>2</sup> Carvedilol also inhibits the contractile response to the  $\alpha_1$ -AR agonist norepinephrine in isolated rabbit aorta ( $K_h = 11 \text{ nM}$ ).<sup>3</sup> It decreases systolic blood pressure and heart rate in rat models of hypertension, including spontaneously hypertensive, renal hypertensive, and deoxycorticosterone acetate-treated rats when administered at doses ranging from 3 to 30 mg/kg. $^4$  Carvedilol also activates cardioprotective signaling through  $\beta$ -arrestin and ERK1/2 activation. $^{5-7}$ It inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), also known as 3C-like protease (3CL $^{pro}$ ; IC $_{50}$  = 204.6  $\mu$ g/ml) and reduces viral infectivity in SARS-CoV-2-infected Vero E6 cells ( $IC_{50} = 0.350 \,\mu g/ml$ ). Formulations containing carvedilol have been used in the treatment of congestive heart failure and hypertension.

#### References

- 1. Baker, J.G. Br. J. Pharmacol. 144(3), 317-322 (2005).
- Groszek, G., Nowak-Król, A., Wdowik, T., et al. Eur. J. Med. Chem. 44(12), 5103-5111 (2009).
- Nichols, A.J., Sulpizio, A.C., Ashton, D.J., et al. Pharmacology 39(5), 327-336 (1989).
- Tanaka, M., Masumura, H., Tanaka, S., et al. J. Cardiovasc. Pharmacol. 10(Suppl 11), S52-S57 (1987).
- 5. Wisler, J.W., DeWire, S.M., Whalen, E.J., et al. Proc. Natl. Acad. Sci. U.S.A. 104(42), 16657-16662 (2007).
- Kim, I.M., Tilley, D.G., Chen, J., et al. Proc. Natl. Acad. Sci. U.S.A. 105(38), 14555-14560 (2008).
- Ibrahim, I.A.A.E.H. and Kurose, H. J. Pharmacol. Sci. 118(4), 408-412 (2012).
- Hamed, M.I.A., Darwish, K.M., Soltane, R., et al. RSC Adv. 11(56), 35536-35558 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 05/17/2023

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM